Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Cabometyx, Cometriq
Cabozantinib is a small molecule tyrosine kinase inhibitor (TKI) that targets multiple receptor tyrosine kinases (RTKs) involved in tumor growth and angiogenesis, including MET, VEGFR2, RET, KIT, AXL, and TIE2. It is used to treat certain types of advanced cancers. By inhibiting these RTKs, cabozantinib disrupts various cellular processes essential for tumor development and spread, such as cell proliferation, survival, and blood vessel formation.
For the treatment of advanced renal cell carcinoma, medullary thyroid cancer, and hepatocellular carcinoma.
Severe and sometimes fatal hemorrhage, gastrointestinal perforations and fistulas, and reversible posterior leukoencephalopathy syndrome (RPLS).
Outcome:
Decreased cabozantinib levels, reduced efficacy
Mechanism:
Increased metabolism of cabozantinib
Outcome:
Decreased cabozantinib absorption
Mechanism:
Altered gastric pH
Outcome:
Increased cabozantinib absorption
Mechanism:
Enhanced solubility
Most likely new formulation: Controlled-release formulation (2025, 60% confidence)
Based on increasing usage in combination therapies and positive clinical trial results, there is a 70% likelihood of expanded indications for cabozantinib in the next 5 years.
Antineoplastic Agent, Kinase Inhibitor
Indolinone derivative